AstraZeneca Seeks Emergency Approval for COVID-19 Antibodies Isolated at VUMC

Translate to Spanish or other 102 languages!

If the EUA is granted, the combination of long-acting monoclonal antibodies, called AZD7442, would be the first to be given to prevent symptoms of COVID-19 and serious illness in people who are infected by the COVID-19 virus, SARS-CoV-2. Image for illustration purposes.

Mega Doctor News

- Advertisement -

by Vanderbilt University Medical Center 

Newswise — The global biopharmaceutical company AstraZeneca said today<October 5> it has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

If the EUA is granted, the combination of long-acting monoclonal antibodies, called AZD7442, would be the first to be given to prevent symptoms of COVID-19 and serious illness in people who are infected by the COVID-19 virus, SARS-CoV-2.

- Advertisement -

The EUA application is based on results of a phase 3 clinical trial, which showed that AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo. Importantly, the trial included immunocompromised and chronically ill adults in whom vaccination against SARS-CoV-2 may not provide sufficient protection against COVID-19.

“This single-shot prevention is likely to be a game changer for at-risk patients,” James Crowe Jr., MD, director of the Vanderbilt Vaccine Center who led the research effort, said when the clinical trial results were released in August.

“The near-term availability of AZD7442 comes at an opportune time,” added Robert Carnahan, PhD, associate director of the Vanderbilt Vaccine Center. “It is clear that we need additional solutions beyond vaccines to protect those most vulnerable members of our society, such as the immunocompromised.”

Delivered by intramuscular injection, the two-antibody treatment was well tolerated with only minor side effects and could afford up to 12 months of protection from COVID-19, company officials said. Preliminary laboratory findings also suggest that AZD7442 can neutralize recent emergent variants of the virus, including the delta variant, they said.

- Advertisement -

The original antibodies that were the basis for the engineered long-acting antibodies that make up AZD7442 were isolated last year at VUMC. Crowe and his colleagues have developed ultra-fast methods for discovering highly potent antiviral human monoclonal antibodies and validating their ability to protect small animals and non-human primates.

Six of the antibodies were licensed to AstraZeneca in June for advancement into clinical development. In October the company announced it was advancing into phase 3 clinical trials an investigational therapy consisting of two long-acting antibodies discovered at VUMC and optimized by AstraZeneca.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

How to Avoid Getting Sick During Holiday Travel

Amid one of the busiest travel weeks of the year, an infectious disease specialist is sharing advice on how to lower your risk of getting sick when traveling this Thanksgiving.

STHS’s Latest “South Texas Healthy Living” Episode to Examine Bladder Health, Nov. 29

Healthy bladder function plays an important role in overall wellness, helping the body eliminate waste efficiently while supporting comfort, restful sleep and an active lifestyle.

Tips for Preventing and Treating Kitchen Cuts This Holiday Season

Preparing a holiday dinner can be as chaotic as it is joyous. A slip while chopping vegetables, peeling potatoes, or carving the turkey can happen even to the most experienced cooks.

STHS Behavioral to Host Webinar on Coping with Holiday Stress, Dec 3

The holiday season is often described as the most wonderful time of the year. However, for many people, it can also bring feelings of stress, sadness, anxiety and loneliness.
- Advertisement -